Scholar Rock is a biopharmaceutical company developing therapies for spinal muscular atrophy and rare neuromuscular diseases by leveraging its proprietary understanding of transforming growth factor beta superfamily biology. The company's lead program is apitegromab, a monoclonal antibody that inhibits myostatin activation in skeletal muscle, with a pipeline that includes additional myostatin inhibitors and early-stage programs for oncology and fibrotic diseases. Scholar Rock does not currently generate product revenue; the company's business model relies on regulatory approval and commercialization of its drug candidates, with revenue potential coming from product sales and collaborations that include milestone payments and royalties.